OPHLY:OTCMKTS
小野藥品工業
US$4.84
arrow_upward
+0.52%(+0.025) 1 天
4月24日, GMT-4 16:00:00 · USD
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 OPHLY 生成关键数据洞见…
开盘价
US$4.89
最高价
US$4.89
最低价
US$4.84
市值
一.一七万亿
平均成交量
三.八七万
成交量
二.〇八万
52 周最高价
US$5.75
52 周最低价
US$3.28
Beta 版
〇.二八
流通股数
一四.九六亿
员工人数
四二八七
新闻报道
来自全网
华尔街日报中文网
·
11分钟前
标普500指数和纳指创下新高，受英特尔股价飙升推动
Seeking Alpha
·
49分钟前
S&P 500 Earnings: A Broken Record - Positive Revisions, Revenue Growth Worth Noting Again
Simply Wall Street
·
1小时前
AppFolio (APPF) Margin Compression Challenges Bullish Growth Narratives After Q1 2026 Results
美国之音
·
2小时前
标普500与纳指创新高坐收，油价涨跌互现，新一轮美伊和谈得到确认
资料
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
小野藥品工業简介